Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for P3 Health Partners (PIIIW) over the last 6 years, with Q3 2025 value amounting to $369.8 million.

  • P3 Health Partners' Cost of Revenue fell 799.44% to $369.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 88.48%. This contributed to the annual value of $1.6 billion for FY2024, which is 2629.15% up from last year.
  • Latest data reveals that P3 Health Partners reported Cost of Revenue of $369.8 million as of Q3 2025, which was down 799.44% from $351.3 million recorded in Q2 2025.
  • P3 Health Partners' Cost of Revenue's 5-year high stood at $410.2 million during Q4 2024, with a 5-year trough of $134.1 million in Q4 2021.
  • In the last 5 years, P3 Health Partners' Cost of Revenue had a median value of $285.6 million in 2023 and averaged $291.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 8129.37% in 2022, then crashed by 799.44% in 2025.
  • P3 Health Partners' Cost of Revenue (Quarter) stood at $134.1 million in 2021, then skyrocketed by 100.68% to $269.2 million in 2022, then surged by 36.59% to $367.7 million in 2023, then rose by 11.57% to $410.2 million in 2024, then decreased by 9.86% to $369.8 million in 2025.
  • Its last three reported values are $369.8 million in Q3 2025, $351.3 million for Q2 2025, and $372.0 million during Q1 2025.